Melina Elpi Marmarelis, MD
Dr. Melina Elpi Marmarelis is a medical oncologist and the Medical Director of the Penn Medicine Mesothelioma and Pleural Disease Program in Philadelphia, Pennsylvania. In addition to overseeing the care of all patients diagnosed with malignant mesothelioma, lung cancer, and other thoracic malignancies, she is also an Innovation Faculty Member at the Penn Center for Cancer Care Innovation, Assistant Professor at the University of Pennsylvania, and Co-Director of the Molecular Tumor Board at the University of Pennsylvania.[1]
Dr. Marmarelis has expertise in a wide range of clinical areas including immunotherapy, chemotherapy, and lung cancer genomics. She has experience in treating diaphragm tumors; patients with EGFR mutations; lung cancer; lung sarcoma; mesothelioma, non-small cell lung cancer; pleural cancer; pulmonary adenocarcinoma; small cell lung cancer; squamous cell lung carcinoma; thoracic cancers; thymoma and thymic carcinomas; and thymus cancer.[2]
Education and Career
Dr. Marmarelis began her education at Dartmouth University, where she earned a Bachelor of Arts degree in Biochemistry and Molecular Biology. She earned her medical degree at Harvard Medical School and then completed an internship and residency in Internal Medicine at Brigham and Women’s Hospital in Boston, Massachusetts. She completed her training with a fellowship in Hematology and Oncology fellowship at the Hospital of the University of Pennsylvania. Dr. Marmarelis is board-certified in Internal Medicine and Medical Oncology.[1]
Professional Memberships and Activities
Dr. Marmarelis is active in several medical societies, as well as in research programs for the pharmaceutical industry and the Department of Defense. These activities include:[2]
- Academic Thoracic Oncology Medical Investigators Consortium, International
- American Society of Clinical Oncology, National
- AstraZeneca, International
- Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) Mesothelioma panel, National
- Ikena, National
- International Association for the Study of Lung Cancer, International
Research
Dr. Marmarelis’ research focuses on early-phase clinical trials in lung cancer and malignant pleural mesothelioma, determinants of therapy resistance and sensitivity, and molecular characteristics and testing in non-small cell lung cancer (NSCLC).[1]
Dr. Marmarelis’ recent publications include:[2]
William Tompkins MD, Connor B. Grady MPH, Wei-Ting Hwang PhD, Krishna Chandrasekhara, Caroline McCoach MD, Fangdi Sun MD, Geoffrey Liu MD, Devalben Patel MD, Jorge Nieva MD, Amanda Herrmann MD, Kristen Marrone MD, Vincent K. Lam MD, Vamsi Velcheti MD, Stephen V. Liu MD, Gabriela Liliana Bravo Montenegro MD, Tejas Patil MD, Jared Weiss MD, Kelsey Leigh Miller MD, William Schwartzman MD, Jonathan E. Dowell MD, Khvaramze Shaverdashvili MD, Liza Villaruz MD, Amanda Cass PharmD, Wade Iams MD, Dara Aisner MD, PhD, Charu Aggarwal MD, D. Ross Camidge MD PhD, Melina E. Marmarelis MD, Lova Sun MD: Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC) JTO CRR: 2024.
Melina E. Marmarelis, Dylan G. Scholes, Cindy M. McGrath, Salvatore F. Priore, Jacquelyn J. Roth, Michael Feldman, Jennifer J.D. Morrissette, Leslie Litzky, Charu Deshpande, Jeffrey C. Thompson, Abigail Doucette, Peter E. Gabriel, Lova Sun, Aditi P. Singh, Roger B. Cohen, Corey J. Langer, Erica L. Carpenter, Charu Aggarwal: Brief Report: Impact of reflex testing on tissue-based molecular genotyping in patients with advanced non-squamous non-small cell lung cancer Clinical Lung Cancer: 2024.
Tejas Patil MD, Alyse Staley MS, Yunan Nie MD, Mandy Sakamoto MD, Margaret Stalker MD, James M. Jurica MD, MBA, Kenna Koehler BA, Amanda Cass PharmD, Halle Kuykendall BA, Emily Schmitt MS, Emma Filar BA, Evelina Reventaite MS, Kurt D. Davies PhD, Hala Nijmeh PhD, Mary Haag PhD, Benjamin A. Yoder PharmD, Paul A. Bunn MD, Erin L. Schenk MD, PhD, Dara L. Aisner MD, PhD, Wade T. Iams MD, Melina E. Marmarelis MD, D. Ross Camidge MD, PhD: The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC JTO CRR: 2024.
Melina E. Marmarelis, Dylan Scholes, Tara L. McWilliams, Wei-Ting Hwang, John Kosteva, Michael R. Costello, Lova Sun, Aditi P. Singh, Kelsey Lau-Min, Abigail Doucette, Peter E. Gabriel, Anthony Martella, Megan Roy, Jeffrey C. Thompson, Roger B. Cohen, David W. Dougherty, Lawrence N. Shulman, Corey J. Langer, Erica L. Carpenter, Charu Aggarwal: Prospective Trial of an EMR-based Nudge to Increase Molecular Genotyping in Newly Diagnosed Metastatic Non-squamous NSCLC IASCLC WCLC 2023, Singapore: 2023.
Se-Hoon Lee, Byoung Chul Cho, Alexander I. Spira, Sai-Hong Ignatius Ou, Saiama N. Waqar, Sujay Shah, Leonardo Trani, Pei-Ling Chu, Meena Thayu, Roland E. Knoblauch, Joshua M. Bauml, Melina E. Marmarelis: Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in Post-TKI EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2 IASLC World Lung conference, Singapore: 2023.
Nikhil Yegya-Raman, Abigail T. Berman, Christine A. Ciunci, Cole Friedes, Eva Berlin, Michelle Iocolano, Xingmei Wang, Ching Lai, William P. Levin, Keith A. Cengel, Shannon E. O’Reilly, Roger B. Cohen, Charu Aggarwal, Melina E. Marmarelis, Aditi P. Singh, Lova Sun, Jeffrey D. Bradley, John P. Plastaras, Charles B. Simone II MD, Corey J. Langer, Steven J. Feigenberg: Phase II trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung cancer: Pembro after PBT ReRT for NSCLC International Journal of Radiation Oncology*Biology*Physics: S0360-3016(23)07846-X.,2023.
Nikhil Yegya-Raman, Cole Friedes, Lova Sun, Michelle Iocolano, Kristine N. Kim, Abigail Doucette, Roger B. Cohen, Kyle W. Robinson, William P. Levin, Keith A. Cengel, Brian Lally, Manuj Agarwal, Christopher A. D’Avella, Melina E. Marmarelis, John A. Kosteva, Aditi P. Singh, Christine A. Ciunci, Charu Aggarwal, Abigail T. Berman, Corey J. Langer, Steven J. Feigenberg: Utilization and factors precluding receipt of checkpoint inhibitor consolidation for stage III NSCLC in a large U.S. academic health system. Clinical Lung Cancer 24 (5): 474-482,2023.
